Viatris Inc. Earnings Recaps
Q2 2026
Aug 10, 2026
Viatris shares fell 6.9% after the quarter as investors reacted negatively to the cautious outlook driven by ongoing manufacturing disruptions and a heightened regulatory burden at its Nashik facility, dampening confidence despite raised guidance.
Key takeaways
- Total revenues grew 3.5% year-over-year to $3.8 billion, reflecting moderate operational growth.
- Adjusted EBITDA reached $1.2 billion, and adjusted EPS was $0.69 per share, both in line with guidance.
- The company raised its 2026 financial guidance midpoint but highlighted intermittent manufacturing disruptions at Nashik following a Q1 fire and FDA inspection in May.
- Initiated a comprehensive remediation plan to address FDA observations, adding near-term execution risk.
- Commercial execution was solid in Greater China and North America, supported by new product approvals and pipeline progress, though these positives were overshadowed by operational challenges.
Q1 2026
May 9, 2026
Viatris shares rose 7.6% following Q1 results, driven primarily by solid execution in Greater China and progress on key product approvals that ease growth concerns. The market rewarded the company's pipeline milestones and commercial momentum despite no major changes to guidance.
Key takeaways
- Reported Q1 revenues of $3.5 billion, up 3% year-over-year, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59 per share.
- Strong commercial execution in Greater China significantly contributed to revenue growth; Japan showed improving momentum with the EFFEXOR launch for generalized anxiety disorder.
- Regulatory progress remains on track with one product approved this quarter and five additional decisions expected in the second half, including the contraceptive patch XULANE LO and fast-acting meloxicam.
- Management emphasized disciplined capital allocation, continuing to balance shareholder returns with investments in growth and pipeline development.
- Strategic initiatives to optimize costs and improve operational efficiency are progressing as planned, supporting margin sustainability.
Q3 2025
Nov 6, 2025
Viatris reported a robust Q3 2025, with solid revenue growth and an increase in full-year guidance, bolstered by strong commercial execution and advancements in its product pipeline.
Key takeaways
- Achieved 1% operational revenue growth (excluding Indore), consistent with expectations, driven by strong performance in Europe and emerging markets.
- Raised full-year guidance for total revenues, adjusted EBITDA, and adjusted EPS due to positive momentum within the business.
- Significant progress in pipeline development, including a forthcoming NDA for fast-acting meloxicam and advancements in Phase III programs for cenerimod and selatogrel.
- Returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, on track to exceed $1 billion in capital returns for the year.
- Strategic review targeting operational efficiencies and growth reinvestment is underway, with opportunities for meaningful cost savings identified.